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Figure 1. Study CONSORT chart 
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Figure 3. Distribution of Modified Rankin scale at 90 days. 
 
  
Summary 
Background: Alteplase given within 4·5 hours of onset is the only approved 
medical treatment in acute ischaemic stroke. Newer thrombolytic agents 
may be advantageous, with higher fibrin specificity, easier administration 
schedules, and longer half-life. Different doses of tenectplase have been 
investigated previously in two small randomised trials in acute stroke in 3 or 
6 hour time windows, in one study using advanced imaging-based patient 
selection. We evaluated the efficacy and safety of tenecteplase versus 
alteplase in a less selected population than previous studies, using imaging 
biomarkers, in order to inform the appropriate design of a definitive clinical 
trial.  
Methods: In a single-centre, phase 2, prospective randomised open-label 
blinded end-point evaluation (PROBE) trial, adult patients with 
supratentorial ischaemic stroke  eligible for intravenous thrombolysis within 
4·5 h of onset received tenecteplase 0·25 mg/kg (maximum 25 mg) or 
alteplase 0·9 mg/kg (maximum 90 mg). Treatment allocation used a mixed 
randomisation/minimisation algorithm including age and NIHSS score, 
generated by an independent statistician. Imaging comprised baseline 
computed tomography (CT), CT perfusion (CTP) and CT angiography (CTA), 
and CT+CTA at 24-48 hours. The primary end-point was penumbral salvage 
(CTP-defined penumbra volume minus follow-up CT infarct volume. 
Results: We recruited 104 patients (52 in each group) over 20 months. In the 
protocol-defined analysis of 96 confirmed stroke patients, groups were 
balanced for clinical characteristics. Among 71 subjects contributing to the 
imaging primary endpoint, no significant differences were observed for 
penumbral salvage [68 (SD 28) % tenecteplase vs 68 (SD 23) % alteplase], 
mean difference 1% (95% confidence interval -10%, 12%, p=0·81) or for any 
secondary end-point. Neither SICH incidence (1/52, 2% vs 2/51, 4%, by SITS-
MOST definition, p=0·55; by ECASS-2 definition, 3/52, 6% tenecteplase vs 4/51, 8% 
alteplase, p=0.59) nor total ICH events differed significantly (8/52 
tenecteplase, 15% vs 14/51 alteplase, 29%, p=0·091). The incidence of 
serious adverse events  did not differ between groups (32 in the 
tenecteplase group, 3 considered probably or definitely related to drug 
treatment; 16 in the alteplase group, 5 considered drug-related).  
Interpretation: Neurological and radiological outcomes did not differ 
between tenecteplase and alteplase. Further evaluation of tenecteplase in 
acute stroke is warranted. 
Funding: The Stroke Association (TSA 2010/04).  
The recombinant tissue plasminogen activator (rtPA) alteplase is the only 
medical treatment currently approved for acute ischaemic stroke, but while 
it significantly improves the likelihood of disability-free recovery, alteplase 
has limited fibrinolytic efficacy, achieving arterial recanalisation in fewer 
than 50% of patients 1. Among those who recanalise, only about half do so 
within two hours of drug administration2. Tenecteplase (TNK) is a modified 
rtPA molecule engineered  to improve efficacy3 through higher affinity 
binding to fibrin, greater resistance to inactivation by Plasminogen Activator 
Inhibitor-1(PAI-1), lack of procoagulant effects, and longer free plasma half-
life. In animal models, it achieved significantly shorter time to reperfusion, 
with greater recanalisation and reduction of thrombus burden compared to 
alteplase 4. In acute myocardial infarction (MI), tenecteplase demonstrated 
equal therapeutic efficacy and lower bleeding risk than alteplase 5, with a 
trend towards better early reperfusion6. 
Investigation of new thrombolytic agents in acute stroke has, until recently, 
concentrated on time periods beyond the 4·5 hour time window from 
symptom onset established for alteplase. Dose-ranging studies of 
tenecteplase in acute stroke have been reported7, 8. Parsons and colleagues 
9 reported superiority of tenecteplase over alteplase in terms of both 
imaging-defined reperfusion and clinical outcomes in a selected group of 
patients with large artery occlusion and favourable brain perfusion patterns 
defined on computed tomography (CT). However, it is unclear how the 
effect sizes observed in a highly selected population will translate into more 
general populations. We undertook a phase 2 randomised, controlled clinical 
trial comparing alteplase with tenecteplase in a thrombolysis-eligible acute 
ischaemic stroke population, using imaging criteria as exploratory outcome 
measures rather than selection criteria, in order to define possible effect 
sizes in a general stroke population eligible for intravenous thrombolysis. 
Methods: 
Study design, Setting and patients 
The trial was a single centre phase 2 Prospective, Randomised, Open, 
Blinded End-point (PROBE) study comparing the efficacy and safety of 
alteplase and tenecteplase in thrombolysis-eligible patients with acute 
ischaemic stroke, using clinical and imaging biomarkers for outcome 
evaluation. The trial was conducted at a regional neurosciences centre 
providing a comprehensive stroke service to a population of approximately 
450,000, with some additional secondary transfers for thombolysis 
assessment from seven regional stroke services. Total admissions are 
approximately 900 per annum, of whom approximately 600 are confirmed 
ischaemic strokes. Thrombolysis numbers average 100 per annum. Clinical 
research staff recruited to the trial and additionally supervised multimodal 
CT acquisitions, including out of hours. 
Patients were eligible if they had clinically diagnosed supratentorial acute 
ischaemic stroke with measurable deficit on the NIH stroke scale (NIHSS),10 
were within 4·5 hours of symptom onset, were aged ≥18 years, were living 
independently pre-stroke, and were considered eligible for intravenous (IV) 
thrombolysis according to clinical guidelines11. Exclusion criteria reflected 
the current evidence regarding contraindications.12, 13 We allowed inclusion 
of those aged >80 years, with minor neurological deficit, previous history of 
stroke and concomitant diabetes, or seizure at stroke onset, as per UK 
guidelines, and with the approval of the UK competent authority. Patients 
with other contraindications for alteplase14, 15 were excluded, as were those 
with estimated Glomerular Filtration Rate (eGFR) < 30 ml/min or known 
iodinated contrast allergy. The protocol was approved by the ethical 
committee responsible for trials involving adults with incapacity (Scotland A 
REC, Reference: 11/SS/0039). This study is registered, NCT01472926. 
Procedure, randomisation and masking 
Written informed consent was given by the patient or their legal 
representative as defined by relevant Adults with Incapacity legislation16. 
Witnessed informed consent was permitted for those with capacity who 
could not sign due to physical impairment. Following non-contrast CT brain 
(NCCT), patients were allocated to receive alteplase (0·9 mg per kilogram to 
a maximum 90 mg, with 10% of dose as initial bolus, followed by 90% over 
one hour infusion) or tenecteplase (0·25 mg per kilogram, to a maximum 25 
mg as a single bolus) using a mixed minimisation/randomisation approach. 
Within each block of 8 patients, 2 were allocated at random (1 to alteplase, 
1 to tenecteplase) and 6 were allocated using minimisation with respect to 
age (≤80, ≥81) and NIHSS score (1-9, 10-15, 16-42). When the minimisation 
algorithm did not favour allocation to either group, the allocation was 
random. The order with which patients were allocated by randomisation or 
minimisation (and the random allocation to be used, if required) was 
defined by a prespecified sequence generated using the method of 
randomised permuted blocks. This sequence was concealed from study 
researchers, and the allocation to treatment groups was obtained by 
telephone to an interactive voice response system (IVRS) developed by the 
Robertson Centre for Biostatistics, University of Glasgow. The computer 
program (and random seed) used to generate the 
minimisation/randomisation sequence was written by a statistician who was 
not involved with the final analysis, and was stored in a secure network 
location with access restricted to staff responsible for the development and 
maintenance of the study IVRS. Clinicians responsible for routine clinical 
care were aware of treatment assignment since drug administration 
schedules differ (additional infusion over 1 hour is required for alteplase 
administration). Patients were not informed of treatment allocation. The 
majority lacked capacity at the time of treatment, and would only have 
been aware of treatment allocation if they had prior knowledge of the 
different modes of drug administration.  
Study imaging 
Additional CT perfusion (CTP) and CT angiography (CTA) were performed at 
baseline. Follow-up imaging comprised NCCT and CTA at 24-48 hours post 
thrombolysis.  
All scans were performed on a Philips Brilliance 64 multidetector scanner. 
Whole brain NCCT was acquired first, (5 mm slice thickness FOV 218 x 218 
mm, 120 kv, 171 mA or 0·9 mm slice thickness, FOV 250x250  mm, 120 kV, 
404 mA) followed by CTP with 40 mm slab coverage from the basal ganglia 
(8x5 mm slices, FOV 25 cm, 80 kVp, 476 mA, 2 second cycle time, 30 cycles) 
using a 50 ml contrast bolus administered at 5 mls per second (350 Xenetix) 
via a large-gauge cannula. A CTA covering aortic arch to the top of the 
lateral ventricles (0·67 mm slice thickness, 120 kV, 475 mA) was acquired 
during the first arterial past of contrast (Xenetix 350, 60 mls, followed by 30 
mls of saline bolus, both given at 5 ml per second). Follow-up CTA covered 
from base of skull to the top of lateral ventricles.  
Outcomes 
We defined the volumes of tissue fulfilling characteristics of the ischaemic 
penumbra (tissue that is hypoperfused but potentially salvageable) and core 
(hypoperfused tissue that will inevitably infarct) based on established 
probabilistic thresholds17 for CT perfusion (CTP). The primary outcome 
measure was the percentage penumbral salvage at 24-48 hour post 
treatment18, 19 using baseline CTP-defined penumbra volume minus final 
infarct volume on follow-up NCCT.  
Secondary outcome measures were infarct volume on 24-48h NCCT (defined 
below, both whole brain infarct volume and co-registered infarct volume); 
the proportion of patients who exhibited recanalisation (Thrombolysis in 
Myocardial Infarction [TIMI] grade 2-3)20 on follow-up CTA21; early clinical 
improvement defined by reduction of NIHSS score of eight points or more, or 
NIHSS score of zero or one at 24-48 hours post treatment, distribution of 
functional outcome on modified Rankin Scale (mRS) at 30 and 90 days, the 
proportion of excellent functional recovery (mRS 0-1) at 30 and 90 days15, 22, 
average “home time” (number of nights spent in non-institutional private 
residence) by 90 days, and mortality at 90 days. Safety outcomes were the 
proportion of patients with Symptomatic Intracerebral Haemorrhage (SICH) 
at 24-48 hours post treatment defined by i) the Safe Implementation of 
Thrombolysis in Stroke Monitoring Study (SITS-MOST)23 criteria (Parenchymal 
haemorrhage (PH) type 2 or remote PH2 on 24-48h NCCT, plus neurological 
deterioration of ≥4 points NIHSS score); and ii) the European Cooperative 
Acute Stroke Study (ECASS) II definition14 (any ICH on follow-up NCCT with 
clinical deterioration); and iii) any ICH. 
NIHSS assessment was performed at baseline, 24-48 hours, 72 hours post 
treatment, and at seven days (or discharge if earlier). Modified Rankin scale 
assessment was performed at 30 days and 90 days via telephone interview. 
All clinical assessments were performed by trained observers. Whilst 
observers performing clinical assessments were not informed of treatment 
allocation at the time of follow-up, as a single-centre trial, blinding to 
treatment allocation for clinical end-points could not be guaranteed.  
Imaging processing and analysis: 
Imaging studies were anonymised, and analysed independently by two 
research fellows blinded to treatment allocation after the recruitment 
completion to minimise the odds of recognising scans with treatment 
allocation. CT perfusion was processed offline using MiStar (Apollo Medical 
Imaging Technology, Melbourne, Australia). Full technical details are 
available as an online supplement. In summary, deconvolution of tissue 
enhancement curves and arterial input function (AIF) selected from the 
anterior cerebral artery was performed using modified singular value 
decomposition (SVD) with compensation for the effects of arterial delay and 
dispersion. Delay time (DT) was determined as previously described. 
Cerebral Blood Flow (CBF) and Cerebral Blood Volume (CBV) were calculated 
from the peak height and area under tissue enhancement curves 
respectively, and Mean Transit Time (MTT) = CBV/CBF. Ischaemic core was 
defined as tissue with reduced CBF (relative CBF <40% of contralesional 
hemisphere) and prolonged delay time (relative DT >2 sec); penumbra 
volume was defined as tissue with relative DT >2 sec but relative CBF ≥ 40% 
of contralateral17.  
Total infarct volumes were calculated from follow-up NCCT covering the 
entire brain.  Follow-up NCCT co-registered with baseline CTP (thus 
restricted to the 4 cm width covered by CTP) was used to obtain  
“coregistered final infarct volume”.  
We used the following definitions: 
• Penumbra volume salvaged = penumbra volume on baseline CTP – 
penumbra volume that infarcted on 24h NCCT;  
• Percentage of penumbra salvaged = (penumbra salvage/penumbra 
Volume) x 100 
Successful recanalisation was defined as TIMI 2-3 on 24h CTA20, 21 
Discrepancies were resolved by the consensus of experienced neurologists or 
neuroradiologists who were also blinded to treatment allocation. 
Scans with ICH of any type were adjudicated independently and categorised 
according to the ECASS II radiological definition14. 
Statistical analysis 
The trial was primarily intended to inform the design of a larger definitive 
study by yielding information on potential recruitment rates, incidence of 
relevant imaging abnormalities, and distribution of outcome events; 
however, a sample size based on imaging parameters was determined, 
assuming that tenecteplase would exhibit a 15% absolute superior 
recanalisation rate compared to alteplase8, 24  with quicker recanalisation. 
We estimated a potential 25% reduction in mean infarct volume (38 ml vs 
49 ml, standard deviation 20ml),25 equating to 52 subjects per group for 80% 
power at a 5% level of significance. The findings were expected to assist in 
deciding whether a definitive trial based on imaging selection criteria or 
clinical features alone would be preferable.  
The primary outcome and other continuous variables were analysed with a 
linear regression model adjusted for the stratification variables of age and 
baseline NIHSS scale. Binary variables were tested using logistic regression 
models, adjusted for the same stratification variables. P-values for 
difference between treatment groups have been extracted from these 
models.  The protocol-defined analysis population comprised all randomised 
patients who had a final diagnosis of stroke, selected as appropriate for a 
phase 2 study using an explanatory  imaging primary end-point. Normally 
distributed variables are described as mean and standard deviation (SD), 
ordinal variables as median and interquartile range (IQR) and categorical 
variables as number and percentage per category. 
Role of the funding source 
The funding body had no role in study design, data collection, analysis, 
interpretation or writing of the report. All authors had access to full study 
data. The responsibility for submission was that of the corresponding 
author, agreed by the Trial Steering Committee. 
 
Results 
Between January 2012 and September 2013, 355 patients were screened 
(Figure 1), of whom 157 were eligible for IV thrombolysis and 104 patients 
were enrolled, 52 assigned to each treatment group. Reasons for exclusion 
are detailed in Figure 1. Eight patients ultimately had a diagnosis of non-
stroke conditions and were excluded from the protocol-defined analysis. 
Groups were well-balanced for clinical baseline characteristics and co-
morbidities (Table 1), had moderate stroke severity (median NIHSS 11 to 
12), and similar onset-to-treatment time at just over three hours. 
Participants randomised to tenecteplase had a larger median core volume 
(20 ml [IQR 2-55] vs 15 ml [IQR 3-40]), and a higher proportion with large 
artery occlusion (internal carotid artery or proximal middle cerebral artery 
occlusion in 26/35 [75%] tenecteplase-treated vs 23/38 [61%] alteplase 
treated) on baseline CTA, although these potential differences were not 
statistically significant. 
One patient assigned to alteplase did not receive study drug after 
randomisation, following clinician review of baseline CT querying minor ICH; 
all other participants received the full dose of study treatment. Excluding 
those with no baseline perfusion lesion or vessel occlusion, 71 had 
technically satisfactory imaging for the primary outcome analysis, and 67 
were suitable for recanalisation assessment. Patients who did not contribute 
to the primary imaging analysis (n=33) were younger (mean age 66 years, SD 
13) and had less severe strokes (median NIHSS score 9, IQR 6-12) than those 
with analysable imaging. 
All patients with confirmed stroke were followed –up for three months after 
study entry.  
Efficacy  
There were no significant differences in the primary endpoint of percentage 
penumbra salvaged (mean difference 1%, 95%CI -10% to 12%, p=0·81), or of 
secondary endpoints, either for imaging or for clinical outcomes (Table 2, 
Figure 3).  
Adding core volume and occlusion site to the regression models as a post-
hoc analysis, did not affect either the primary outcome (mean difference 
2·5%, 95%CI -8%,13%, p=0·65) or recanalisation rates (OR 0·7, 95%CI 0·2-2·2, 
p=0·65) (details of recanalisation by occlusion site given in Supplementary 
material Figure). 
Safety outcomes 
The safety population included 52 treated with tenecteplase and 51 treated 
with alteplase. Intracerebral haemorrhage (ICH) of any kind was seen in 
eight patients in the tenecteplase group and 14 in the alteplase group (OR 
0·4, 95%CI 0·2-1·2, p=0·09); only one Parenchymal Haemorrhage (PH)14 
occurred in the tenecteplase group, compared to five in the alteplase 
group.  Symptomatic ICH incidence, using either SITS-MOST definition or 
ECASS II definition, did not differ (Table 2).  
There were 32 Serious Adverse Events (SAEs) in 22 (42%) patients given 
tenecteplase and 16 SAEs in 16 (31%) patients given alteplase, including ICH 
events fulfilling criteria for seriousness (Table 3). Details of  non-serious AEs 
are given in the supplementary material.  
Discussion 
Neither radiological nor clinical outcomes differed significantly with IV 
tenecteplase 0·25 mg/kg compared to alteplase 0·9 mg/kg, the current 
standard of care. We found no difference in our primary end-point of 
penumbral salvage, an exploratory measure selected due to its established 
relationship to early clinical change26. Safety outcomes did not differ, 
notably intracerebral haemorrhages of all kinds, and parenchymal 
haematomas, the complication most strongly associated with treatment-
related neurological deterioration27. 
A combined randomisation/minimisation approach using clinical variables 
produced groups balanced for clinical factors but advanced imaging 
identified potential baseline imbalances, such that the tenecteplase group 
included a higher proportion of patients with large artery occlusion 
(therefore lower probability of favourable response to treatment1) and 
larger ischaemic core (therefore higher risk of haemorrhagic 
complications28). While it is possible that a larger sample size would even 
out such differences in phase 3 trials, this finding argues strongly for 
inclusion of advanced imaging to fully characterise patients in phase 2 
studies. Identifying the baseline imbalance in important prognostic variables 
is potentially relevant to the interpretation of our neutral results with 
respect to efficacy and safety.  
The study population in ATTEST differed from previous trials of alteplase 
with respect to age, comorbidities and stroke severity, reflecting wider use 
of alteplase in current clinical practice.13 Safety outcomes in the alteplase 
arm were comparable to previous experience with respect to mortality and 
SICH incidence.23 We observed fewer very favourable outcomes than in 
studies with similar onset to treatment time (mRS 0-1 was achieved in 52% 
in ECASS-3 and in 41% in SITS-ISTR, compared to 20% in our study). This 
likely reflects a population with greater age at baseline in our sample (mean 
age 65 years in both of these studies compared to 71 years in ours) and a 
higher proportion with prognostically important age-related comorbidities 
such as atrial fibrillation; in addition we had a notably higher proportion of 
severe stroke syndromes even compared to more recent trials (57% TACS in 
our study compared to 42-44% TACS in IST-3).  
We selected a dose of tenecteplase of 0·25 mg/kg based on available data7, 
8, 24, 29 although numbers of randomised subjects in previous studies were 
small. One previous study24 terminated investigation of a higher dose (0·4 
mg/kg) due to possible increased SICH incidence (3 in 19 patients). The 
same study suggested more frequent good outcomes with 0·25 mg/kg 
compared to 0·1 mg/kg, and Parsons and colleagues29 also found superior 
efficacy of 0·25 mg/kg compared to 0·1 mg/kg, with no additional 
haemorrhagic risk. 
We used advanced CT imaging for outcome analysis to offer insights into 
biological efficacy with modest sample size, but did not use imaging for 
patient selection. This differs from the approach of Parsons and 
colleagues29, who demonstrated superiority of tenecteplase over alteplase 
for both reperfusion and clinical outcomes in a small randomised controlled 
trial that compared two different tenecteplase doses to standard alteplase. 
Their study used multimodal CT imaging to identify what is proposed to be a  
“responder” population in acute stroke, with favourable core:penumbra 
“mismatch” ratios, small ischaemic cores, and intracranial vessel occlusion, 
a strategy that has been expected to reduce sample size in phase two 
trials30, but which limits generalisability. Parsons’ imaging selection criteria 
resulted in exclusion of 79% of IV rtPA-eligible patients, and ultimately only 
12% of treatment-eligible patients were randomised, compared to 66% of 
patients in our study. Less restrictive inclusion criteria resulted in our 
patients having larger core (median [IQR] 14 ml [0-41] compared to 10 ml 
[5-17] in Parsons’ study, and smaller penumbra volumes (median [IQR] 53 ml 
[0-110] compared to 79 ml [56-100], with only 64% (67/104) baseline vessel 
occlusion. In our study, 19% of patients had either acute ICA occlusion or a 
thrombus involving the terminal ICA extending to the proximal MCA 
segment, an arterial target lesion that responds poorly to intravenous 
thrombolysis31, while these patients were excluded from their study.  
The application of advanced imaging for outcome assessment in acute 
stroke trials has strengths and limitations. Limitations of this study included 
use of non-contrast CT to quantify final infarct, since the extent of the 
ischaemic lesion often remains poorly defined at 24h on this modality, 
restricted brain coverage for CT perfusion in most hospitals, and reliance on 
probabilistic thresholds to define core and penumbra that have only limited 
validation32, 33. MRI has high sensitivity in defining the extent of infarction34, 
and greater lesion conspicuity at early time points than CT, but this is at the 
expense of poorer availability, and some additional bias in patient selection 
due to exclusion of patients with ferromagnetic implants including 
pacemakers, and difficulties in managing acutely unwell patients in the MRI 
environment32. Imaging selection criteria inevitably introduce some delay in 
treatment initiation for acquisition, processing and interpretation of 
additional scans, and thus may compromise treatment efficacy.When used 
as a biomarker for relevant outcomes (reperfusion, recanalisation, and 
tissue salvage) additional imaging offers valuable insights in phase two 
evaluation. Our selected imaging end-points used penumbral salvage as the 
primary end-point due to its close correlation with clinical change18, 19.  
Recanalisation is a powerful predictor of outcome35 but early recanalisation 
and reperfusion are more relevant than late, and repeat imaging studies are 
often less practical when required within the first few hours of treatment. 
The optimal imaging biomarker remains uncertain. With respect to phase 3 
trial design, additional imaging analyses may lead to significant loss of 
evaluable subjects from a trial. Even with a single centre study familiar with 
the techniques, 30% of recruited patients did not contribute to imaging 
analyses, the great majority of these due to absence of an initial perfusion 
lesion or vessel occlusion. In a multicentre trial, the proportion of non-
evaluable subjects is likely to be increased further. While baseline imaging 
characteristics offered additional insight into stroke severity beyond clinical 
criteria, delaying treatment initiation in order to review imaging findings for 
patient selection pre-randomisation may be detrimental. Standardisation of 
image processing remains poor, and has compromised previous multicentre 
trials36 although software to enable rapid and standardised processing of 
both MRI and CT perfusion imaging has been developed.37 37A phase 3 trial of 
conventional intention-to-treat approach should include allowance for 
recruitment of stroke mimics. Since we did not use imaging to select 
patients in the current study, we are also able to estimate the likely 
proportion of mimics. 
Even if the efficacy of tenecteplase does not differ from alteplase, greater 
ease of administration alone may offer a significant advantage for 
tenecteplase over alteplase, for which delays between initial bolus and 
initiation of maintenance infusion are common and may compromise 
effectiveness; further investigation of tenecteplase for acute ischaemic 
stroke is merited.  
 
 
Research in Context 
Systematic Review 
We searched Medline from inception to December 8th 2014 for articles 
published in any language with the search terms "tenecteplase", "ischaemic 
stroke", and "clinical trial or study ", excluding articles on pulmonary 
embolism, acute myocardial infarction or cardiac failure, to identify 
publications reporting the use of tenecteplase for treatment of acute 
stroke. The search identified two randomised, controlled trials comparing 
alteplase with different doses of tenecteplase 24, 29, a non-randomised 
ascending dose safety study of tenecteplase 7, a single-centre case series of 
low dose tenecteplase (0.1mg/kg) in late-presenting patients selected by 
multimodal CT imaging 8 and one case series of intra-arterial tenecteplase 
treatment 38.  
The ascending dose safety study had no active comparator and tested doses 
from 0.1mg/kg to 0.5mg/kg, with SICH as the main end-point.7 Both RCTs 
evaluated more than one dose of tenecteplase: 31 24 and 25 patients29 were 
treated at the 0.25mg/kg dose. Imaging selection criteria in the trial of 
Parsons and colleagues resulted in exclusion of 79% of IV rtPA-eligible 
patients, a further 9% of whom were not randomised due to open IV 
thrombolytic or endovascular treatment. A 2013 Cochrane review39 included 
summary data from these trials. The trial of Haley and colleagues included a 
higher dose tenecteplase group (0.4mg/kg) to which recruitment was 
discontinued due to safety concerns about SICH incidence at that dose, 
therefore summary data including all dose levels may exaggerate SICH 
incidence. Key characteristics of these trials compared with ATTEST are  
given in the supplementary material Table, and the effects on death and 
disability (mRS 3-6) compared below: 
 
Death or dependence at 3 months (mRS 3-6)
Tenecteplase versus Alteplase
0.2 0.5 1 2
Favours Tenecteplase Favours Alteplase
TNK Alteplase OR (95% CI)
Haley et al 45/81 18/31 0.96 (0.69, 1.42)
Parsons et al 14/50 14/25 0.50 (0.29, 0.89
ATTEST 30/47 30/49 1.04 (0.76, 1.43)
combined 
[random]
89/178 62/105 0.85 (0.58, 1.23)
 
 
 
  
Interpretation 
No previous study has compared a single dose of tenecteplase against 
alteplase with current clinical selection criteria in a 4.5h time window. Our 
results inform the limitations of imaging-based end-points in phase 2 clinical 
trials where imaging has not also been used to select patients, and the 
potential importance of extended imaging to ensure biological 
characterisation in phase 2 trials, where clinical features alone may disguise 
important prognostic differences. Clinical outcomes give more 
representative data on which to base a phase 3 trial.  
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Table 1. Demography, risk factors and stroke characteristics in the per 
protocol population. 
  Tenecteplase 
(n=47) 
Alteplase 
(n=49) 
Clinical 
Age years mean(SD*) 71 (13) 71 (12) 
Male (n, %) 30, 64% 31, 63% 
Dominant hemisphere stroke (n, %) 24, 51% 26, 53% 
Baseline NIHSS (Median, IQR)[min-max] 12 (9-18)[2-26] 11 (8-16)[3-27] 
Onset to Treatment 
Time min  
mean(SD) 184 (44) 
 
192 (45) 
Median (IQR) 180 (156, 215) 200 (160, 220) 
Time between Initial and Follow-up 
Imaging (hours) 
mean (SD) 
28·5 (7·1) 27·3 (7·5) 
Door to Needle Time min mean(SD) 42(17) 38 (19) 
Previous stroke/TIA (n, %) 12, 26% 11, 22% 
Hypertension (n, %) 20, 43% 28, 57% 
Diabetes (n, %) 7, 15% 7, 14% 
Blood glucose mmol/L mean (SD) 7 (1) 7 (2) 
Atrial Fibrillation (n, %) 19, 40% 15,31% 
Hyperlipidaemia (n, %) 4, 9% 7, 14% 
Smoker (n,% ) 13, 28% 10,20% 
Stroke clinical syndrome 
TACS (n, %) 27, 57% 28, 57% 
PACS (n, %) 16, 34% 16, 33% 
LACS (n, %) 2, 4% 3, 6% 
POCS (n, %) 2, 4% 2, 4% 
ASPECT score mean (SD) 7 (2) 7 (2) 
Imaging  
 Penumbra 
Volume ml  
Median (IQR) 40 (4-62) 37 (9-69) 
Mean (SD) 53 (31) 49 (30) 
Core Volume ml  Median (IQR) 20 (2-55) 15 (3-40) 
Mean (SD) 32 (36) 24 (29) 
Occlusion (n,% ) 35/47, 74% 38/49, 78% 
Tandem/ICA 10/35,29% 8/38, 21% 
M1§ 16/35, 46% 15/38, 40% 
M2§ 6/35, 17% 11/38, 29% 
M3§ 1/35, 3% 3/38, 8% 
ACA/PCA 2/35, 6% 1/38, 3% 
*SD, standard deviation; NIHSS: National Institute of Health Stroke Scale; IQR: Interquartile 
Range; TIA: Transient Ischaemic Attack; TACS; Total Anterior Circulation Syndrome; PACS: 
Partial Anterior Circulation Syndrome; LACS: Lacunar Syndrome; POCS: Posterior Circulation 
Syndrome; ASPECT score: Alberta Stroke Program Early CT score; ICA: Internal Carotid 
Artery; § Middle Cerebral Artery M1, M2, M3 segment; ACA: Anterior Cerebral Artery; PCA: 
 
 
Posterior Cerebral Artery. 
Table 2. Study outcomes in the protocol-defined population.  
 
 
Tenecteplase 
(n=47) 
Alteplase 
(n=49) 
p value¢ Mean difference 
(95%CI) 
Odds Ratio 
(95%CI) 
Primary outcome  
Percent penumbral salvage at 24-48 h mean 
(SD)* 
68% (28) 68% (23) 0·81 1·3% (-10-12) - 
Secondary imaging outcomes   
Co-registered final infarct volume at 24-48 h ml 
mean (SD )# 
50 (62) 47 (62) 1.00 0·1 (-20, 20) - 
Total infarct volume at 24-48 h ml mean (SD )Q 75 (101) 66 (91) 0·75 5 (-26, 35) - 
Recanalisation at 24-48 h (n, %)§ 21/32, 66%¤ 26/35, 
74%¤ 
0·38 - 0·6 (0·2-1·8) 
Secondary clinical outcomes  
Early neurological improvement at 24 h (n, %) ¶ 19/47, 40% 12/49, 24% 0·10 - 2.1 (0.9-5.2) 
Improvement in NIHSS between baseline and 24 
h mean (SD) 
3 (6) 2 (6) 0·74 -0·4 (-3-2) - 
mRS at 30 Days (n, %)      
mRS 0-1  7/47, 15% 7/49, 15% 0·89 - 1·1 (0·3-3·5) 
mRS 2-3 20/47, 43% 21/49, 44%    
mRS 4-5 15/47, 32% 14/49, 29%    
mRS 6 5/47, 11% 6/49, 13%    
mRS 0-1 at 90 days (n, %) 13/47, 28% 10/49, 20% 0·28 - 1·8 (0·6-5·5) 
      
  Home by 90 days (n, %) 30/47, 64% 36/49, 73% 0·36 - 0·6 (0·2-1·8) 
Days at home by 90 days mean (SD ) 45 (39) 50 (36) 0·64 -3·1 (-16-10) - 
Mortality at 90 days (n, %) 8/47, 17% 6/49, 12% 0·51 - 1·3 (0·4-3·7) 
Safety outcomes (A=51, T=52)  
Any ICH (n, %) 8/52, 15% 14/51, 27% 0·09 - 0·4 (0·2-1·2) 
Any parenchymal haemorrhage (n, %) 1/52, 2% 5/51, 10% 0·12   
Parenchymal haemorrhage type 2 (n, %) 0/52, 0% 3/51, 6% 0·94   
Symptomatic ICH (ECASS II14 definition) (n, %) 3/52, 6% 4/51, 8% 0·59 - 0·6 (0·1-3·2) 
Symptomatic ICH (SITS-MOST23 definition) (n, %) 1/52, 2% 2/51, 4% 0·50 - 0·4 (0·04-5·1) 
*SD, standard deviation; NIHSS: National Institute of Health Stroke Scale; IQR: Interquartile Range; ICH: 
Intracerebral haemorrhage; mRS: Modified Rankin Scale; 
¢ p-values were calculated from linear of logistic regression models that adjust for stratification variables and are a 
test for difference between groups. 
# Co-registered infarct volume was defined as infarct volume measured on 24-48 h CT slices co-registered to 
baseline CT perfusion; 
QTotal infarct volume was defined as total infarct volume measured on follow-up CT at 24-48 h;  
§ Recanalisation was defined as TIMI21 2-3; 
¤ The percentages for recanalisation were derived from the number of subjects with an occlusion. 
¶ Early neurological improvement at 24 h was defined as NIHSS reduction e 8 points or 24 h NIHSS 0-1. 
Odds ratios for PH or PH2 ICH were not calculated. 
 
Table 3: Serious Adverse Events during the trial period: 
 
 
 
 
 
 
 Tenecteplase 
N=52 
Alteplase 
N=51 
Serious Adverse Events 
All SAEs to day 90 32 16 
All SAEs  within 7 days 8 9 
Probably or definitely related to 
study drug 
3 5 
  
 n 
Up to day 7 8 9 
Angioedema 1 0 
New ischaemic stroke 2 0 
Epistaxis 1 0 
Pneumonia 2 2 
ICH 1 5 
Other   
Chest pain 1 0 
Malignant glioma 0 1 
General deterioration 0 1 
 
 
  
Days 7-90 24 7 
GI Bleeding 2 0 
New ischaemic stroke 4 2 
Other extracranial bleeding 2 0 
Pneumonia 2 0 
Venous thromboembolism 1 0 
Other   
Atrial fibrillation 3 1 
Abdominal pain, constipation , 
diarrhoea 
3 0 
Chest pain 3 0 
Gastroenteritis 0 1 
Fall 1 1 
Planned medical procedures 5 1 
Dehydration 1 0 
Depression 0 1 
Renal impairment 3 0 
Hypotension 2 0 
 Figure 1. Study CONSORT chart 
IV=Intravenous; ICH=Intracerebral Haemorrhage; rtPA: Recombinant tissue plasminogen activator; 
eGFR=Estimated glomerular filtration rate; mRS=Modified Rankin scale; A=Alteplase; T=Tenecteplase; 
CTA=CT angiography; CTP=CT perfusion; NCCT=Non-contrast CT.  
 
 
  
 
Figure 2. Baseline CT perfusion lesion segmented into core and penumbra and co-registered final infarct 
volumes at 24-48 hours. Error bars show standard deviation. 
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Figure 3.  Distribution of Modified Rankin scale at 90 days. 
The number in each category is the absolute number.Definitions of scores: 0=no symptoms at all. 1=no 
significant disability despite symptoms; able to carry out all usual duties and activities. 2=slight disability; 
unable to carry out all previous activities but able to look after own affairs without assistance. 3=moderate 
disability; requiring some help, but able to walk without assistance. 4=moderately severe disability; unable 
to walk without assistance, and unable to attend to own bodily needs without assistance. 5=severe disability; 
bedridden, incontinent, and requiring constant nursing care and attention. 6=dead. 
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Full Inclusion and Exclusion Criteria 
 
Main inclusion criteria 
 Clinical diagnosis of supratentorial acute ischaemic stroke with score of  1 on the NIH 
Stroke Scale 
 Male or non‐pregnant female ≥18 years of age 
 Within 4.5 hours of onset as defined by time since last known well 
 CTP and CTA examinations acquired prior to treatment 
Main exclusion criteria 
 
 Contraindications to thrombolytic drug treatment for stroke 
o Evidence of intracranial haemorrhage or significant non‐stroke intracranial 
pathology (including CNS neoplasm, aneurysm or AVM) on pre‐treatment CT 
o Established hypodensity on pre‐treatment brain CT of more than one third of the 
MCA territory or ASPECT score <4 (sulcal effacement or loss of grey‐white 
differentiation in cortical territories alone are not counted towards ASPECT score) 
o Hypodensity consistent with recent cerebral ischaemia other than the presenting 
event  
o Very severe stroke (eg NIHSS>25) 
o systolic blood pressure> 185 or diastolic BP> 110 mm Hg, or aggressive management 
(intravenous pharmacotherapy) necessary to reduce BP to these limits 
o If on warfarin, INR <1.4  
o Current prescription of non‐warfarin oral anticoagulant drugs 
o Significant abnormality of coagulation parameters pre‐treatment (prolonged INR or 
APTT, or platelet count <100,000/mm3) 
o administration of heparin within the previous 48 hours and a thromboplastin time 
exceeding the upper limit of normal for laboratory, or use of therapeutic dose low 
molecular weight heparin within 48h 
o Clinical history suggestive of subarachnoid haemorrhage even if no blood is evident 
on CT 
o Risk of bleeding (Major surgery within previous 1 month; intracranial or spinal 
surgery; recent trauma to the head or cranium; prolonged cardiopulmonary 
resuscitation (> 2minutes) within the past 2 weeks; acute pericarditis and/or 
subacute bacterial endocarditis; acute pancreatitis; severe hepatic dysfunction, 
including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and 
active hepatitis; active peptic ulceration; any known history of haemorrhagic stroke 
or stroke of unknown origin; arterial aneurysm and known arteriovenous 
malformation) 
o Dependent (mRS 3‐5) pre‐stroke 
o Blood glucose <2 mmol/l or >18 mmol/l 
o Seizure at onset of symptoms unless brain imaging identifies positive evidence of 
significant brain ischaemia (eg CTA confirmed arterial occlusion, early ischaemic 
change on plain CT, hypoperfusion on CTP) 
o Pregnancy 
 Known impaired renal function (eGFR <30 ml/min) precluding contrast CT 
 Known allergy to radiological contrast 
 History of allergies to active substances in either trial medication, or to excipients including 
gentamicin 
 Severe concurrent medical condition that would prevent participation in study procedures 
(e.g. cardiac failure with severe pulmonary oedema) or with life expectancy ≤ 3 months. 
 
 
 
 
Image Analysis Methods: Additional Details 
The contralesional anterior cerebral artery and superior sagittal sinus were selected for Arterial 
Input Function (AIF) and Venous Output Function (VOF) respectively to obtain the tissue 
enhancement curve. Deconvolution of the tissue enhancement curve and AIF was performed using a 
modified singular value decomposition (SVD) with compensation for the effects of arterial delay and 
dispersion1. A series of delay time values, DTi ranging from zero to Tmax were applied and for each 
delay time value a modelled arterial transport function was convolved with the measured global AIF 
to produce AIFi which is used for SVD deconvolution of the tissue curve to produce an impulse 
residue function IRFi with its maximum appearing at Tmax (i). Delay time (DT) was determined as the 
minimal DTi value which produces Tmax (i) =0. Cerebral Blood Flow (CBF) and Cerebral Blood 
Volume (CBV) were calculated from the peak height and area under the curve of the tissue 
enhancement curves respectively with Mean Transit Time (MTT) = CBV/CBF. Motion correction was 
applied automatically. A noise elimination technique “clustering analysis” of < 10 mm² was used to 
minimise small artifactual pixels induced by noise2. After AIF and VOF selection a Hounsfield Unit 
filter was applied in order to mask cerebrospinal fluid (CSF) and bone, leaving only brain parenchyma 
as far as possible. Voxels with CBV values > 90 cm³/100 g were then masked to improve the accuracy 
of CTP maps3. Ischaemic core was defined as tissue with reduced CBF (relative CBF < 40% that of 
contralesional hemisphere) and prolonged delay time (DT; relative DT > 2 sec); penumbra volume 
was defined as tissue with prolonged DT only (relative DT > 2 sec) but relative CBF ≥ 40% of 
contralateral4.  
Follow‐up NCCT was used to determine outcome infarct volume and presence of ICH. A rigid body 3‐
D transformation was used to register the follow up NCCT imaging to the baseline perfusion scan. 
Structural CT sequences were reformatted manually and visually verified to match the orientation of 
the original CTP. Reformatted structural CT slices resulting from co‐registration were used to 
measure final infarct volume with manually drawn ROIs using visual inspection. Co‐registered final 
infarct volume rather than total infarct volume was used to calculate penumbral salvage because of 
the limited anatomical coverage of CT perfusion acquired with a 4 cm detector. 
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Table: Adverse events during the study period. *SAE listings exclude ICH events, which are described 
in Table 2 in detail. Total SAE numbers include ICH events meeting criteria for seriousness. 
 
  Tenecteplase 
N=52 
Alteplase 
N=51 
Serious Adverse Events* 
All SAEs to day 90  32  16 
All SAEs  within 7 days  8  5 
Probably or definitely related to 
study drug 
3  5 
Subjects with at least one AE n (%)  22 (42%)  16 (31%) 
   
Category  n (latency of the event, days) 
Extracranial Bleeding     
Upper gastrointestinal haemorrhage  1 (60)  0 
Rectal haemorrhage  1 (70)  0 
Epistaxis  1 (0)  0 
Post‐menopausal bleeding  1 (53)  0 
Other Possible Treatment‐Related 
Anaphylactoid reaction  1 (0)  1 (0) 
Stroke‐Related     
Atrial fibrillation  4 (62, 86, 84, 86)  2 (62, 96) 
Pneumonia  4 (0, 33, 21, 1)  2 (1, 1) 
Pulmonary Embolism  1 (18)  0 
Urinary sepsis  1 (50)  0 
Further ischaemic stroke  3 (45, 14, 1)  2 (14, 44) 
Significant Neurological 
deterioration 
3 (0, 2, 0)  1 (1) 
Other     
Dehydration  1 (24)  0 
Decreased mobility  0  1 (28) 
Malignant glioma  0  1 (0) 
Non‐cardiac chest pain  1 (63)  0 
Viral gastroenteritis  0  1 (44) 
Depression  0  1 (51) 
Renal impairment  2(71, 24)  0 
General physical health 
deterioration 
0  1 (67) 
Abdominal pain  1 (70)  0 
Uterus biopsy  1 (53)  0 
Carotid endarterectomy  1 (12)  1 (11) 
Joint resurfacing surgery  1 (88)  0 
 
Total Adverse Events (including serious) 
All AEs to day 90  110  76 
Probably or definitely related to 
study drug 
3  7 
Subjects with at least one AE n (%)  42 (81%)  36 (71%) 
MEDRA classification  Incidence (n AEs) 
Blood  1  0 
Cardiac  6  6 
 
 
Congenital (ASD)  1  0 
Eye  0  1 
GI  8  6 
General Disorders  3  5 
Hepatobiliary  0  1 
Infections  13  7 
Injury  5  5 
Investigations  3  0 
Metabolic/ Nutritional  3  0 
Musculoskeletal  3  5 
Neoplasms  0  1 
CNS  17  17 
Psychiatric  4  2 
Renal & Urinary  5  1 
Respiratory  11  9 
Skin  1  1 
Procedures  4  2 
Vascular  7  2 
 
Table: Characteristics of prior randomised studies comparing alteplase and tenecteplase in acute 
ischaemic stroke. 
 
 
 
Study  Time 
Window 
TNK Dose Levels  Death or Dependence 
(mRS 3‐6) 
SICH 
      TNK  Alt  TNK  Alt 
Haley  3h  0.1mg/kg (n=31); 
0.25mg/kg (n=31); 
0.4mg/kg (n=19) 
45/81  18/31  5/81  1/31 
Parsons  6h  0.1mg/kg (n=25); 
0.25mg/kg (n‐25) 
14/50  14/25  2/50  3/25 
ATTEST  4.5h  0.25mg/kg (n=47)  30/47  30/49  1/52  2/51 
 
Figure: Recanalisation rates according to treatment groups and occlusion sites (percentage within 
each treatment group shown). 
 
 
ICA=Internal carotid artery; M1=Middle cerebral artery first segment; M2=Middle cerebral artery 
second segment; M3=Middle cerebral artery third segment; ACA=Anterior cerebral artery; 
PCA=Posterior cerebral artery. Numbers within each bar represent numbers of subjects. 
 
